GlassScriptPhysician profile
Dan Veljovich
NPI 1770535833
$780,012.96
in general payments reported to CMS, 2019-2025
13 companies · $120K in 2025
The $120K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153K · 2020: $55K · 2021: $73K · 2022: $125K · 2023: $116K · 2024: $138K · 2025: $120K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $271K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $45K · Travel and Lodging: $40K · Consulting Fee: $9,629 · Food and Beverage: $8,428 · Gift: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $270,847.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $45,410.00 |
| Travel and Lodging | $39,685.23 |
| Consulting Fee | $9,628.75 |
| Food and Beverage | $8,428.04 |
| Gift | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $290,530.57 | 2019-2025 | Lynparza, Imfinzi |
| Glaxosmithkline, LLC. | $178,357.05 | 2020-2025 | Jemperli, Zejula |
| Seagen INC. | $92,644.15 | 2021-2023 | Tivdak |
| Eisai INC. | $76,938.70 | 2022-2025 | |
| Tesaro, INC. | $72,597.17 | 2019 | |
| Merck Sharp & Dohme LLC | $39,993.85 | 2019-2023 | Keytruda, Lynparza |
| Abbvie INC. | $13,752.79 | 2024-2025 | |
| Pfizer INC. | $7,403.44 | 2024-2025 | |
| Genentech USA, INC. | $5,611.10 | 2019 | |
| Intuitive Surgical, INC. | $1,143.25 | 2022-2023 | |
| Clovis Oncology, INC. | $716.79 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $244.10 | 2023-2024 | Mychoice Cdx, Precisetumor |
| Astrazeneca Uk Limited | $80.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Veljovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.